seqid	type	start	end	name	nt_name	gene	mutation_type	reference_seq	variant_seq	ao	dp	ro	viral_lineage	function_category	citation	comb_mutation	function_description	clade_defining	who_label	voc_status
MN908947.3	snp	241	241	c.C-25T	c.C-25T	orf1ab		C	T	3267	3269	2	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	1498	1498	p.F411F	c.C1233T	orf1ab	SILENT	C	T	3264	3278	14	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	1807	1807	p.G514G	c.A1542G	orf1ab	SILENT	A	G	3229	3240	11	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	2659	2659	p.K798K	c.G2394A	orf1ab	SILENT	G	A	3264	3277	13	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	3037	3037	p.F924F	c.C2772T	orf1ab	SILENT	C	T	3277	3279	2	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	6285	6285	p.T2007I	c.C6020T	orf1ab	MISSENSE	C	T	3263	3273	10	B.1.525	""""""	""""""		""""""	True	Eta	VOI
MN908947.3	snp	8593	8593	p.V2776V	c.T8328C	orf1ab	SILENT	T	C	3276	3278	2	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	9565	9565	p.F3100F	c.C9300T	orf1ab	SILENT	C	T	3073	3237	164	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	del	11287	11288	p.S3675_F3677del	c.11023_11031delTCTGGTTTT	orf1ab		GTCTGGTTTTA	GA	3177	3208	12	B.1.525	""""""	""""""		""""""	True	Eta	VOI
MN908947.3	complex	14407	14408	p.4716	c.CC14142_14143TT	orf1ab		CC	TT	3269	3277	4	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	18171	18171	p.A5969V	c.C17906T	orf1ab	MISSENSE	C	T	3269	3275	6	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	20724	20724	p.X6820WextX?	c.A20459G	orf1ab	MISSENSE	A	G	3267	3278	10	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	21717	21717	p.Q52R	c.A155G	S	MISSENSE	A	G	2561	2615	54	B.1.525	"""transmissibility"""	"""Albertsen et al. (2021) """	'E484K', 'Q677H', 'F888L'	"""The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021)."""	True	Eta	VOI
MN908947.3	complex	21762	21765	p.A67_V70delinsVI	c.CTATACATGT200_209TTAT	S		CTATACATGT	TTAT	3173	3215	22	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	del	21990	21994	p.Y145del	c.432_434delTTA	S		TTTATTAC	TTTAC	3079	3123	32	B.1.525	"""convalescent plasma escape"""	"""McCarthy et al. (2021) """		"""Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient."""	False	Eta	VOI
MN908947.3	del	21990	21994	p.Y145del	c.432_434delTTA	S		TTTATTAC	TTTAC	3079	3123	32	B.1.525	"""convalescent plasma escape"""	"""Li et al. (2020) """		"""Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)"""	False	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""T cell evasion"""	"""Reynolds et al. (2021) """		"""Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Sun et al. (2021) """		"""Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Collier et al. (2021) """		"""Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Li et al. (2021) """		"""Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Gaebler et al. (2021) """		"""Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. """	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Liu et al. (2020) """		"""Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Wang et al. (2021) """		"""Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Chen et al. (2021) """		"""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Wang et al. (2021) """		"""Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""antibody epitope effects"""	"""Rappazzo et al. (2021) """		"""Massive reduction in binding efficiency vs wild type for mAb LY-CoV555."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""ACE2 receptor binding affinity"""	"""Tian et al. (2021) """		"""Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd "	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""ACE2 receptor binding affinity"""	"""Zahradnik et al. (2021) """		"""Among the first selected variants in an in vitro evolution experiment for ACE2 binding."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""ACE2 receptor binding affinity"""	"""Starr et al. (2020) """		"""Experimentally, ACE2 binding affinity increased 0.06 fold"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""trafficking"""	"""Kuzmina et al. (2021) """	'D614G'	"""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""trafficking"""	"""Ferriera et al (2021) """		"""This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. """	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""trafficking"""	"""Tada et al. (2021) """		"""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""pharmaceutical effectiveness"""	"""Engelhart et al. (2021) """		"""Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Tada et al. (2021) """	'D614G'	"""Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Tang et al. (2021) """		"""As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Tada et al. (2021) """		"""The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Alenquer et al. (2021) """		"""Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Zhou et al. (2021) """		"""Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Liu et al. (2021) """		"""Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Wang et al. (2021) """		"""The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""convalescent plasma escape"""	"""Andreano et al. (2020) """		"""This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""transmissibility"""	"""Albertsen et al. (2021) """	'Q52R', 'Q677H', 'F888L'	"""The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021)."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Tada et al. (2021) """	'D614G'	"""Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Solfrosi et al. (2021) """		"""Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). """	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Ikegame et al. (2021) """		"""E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Jangra et al. (2021) """		"""Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. """	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Kuzmina et al. (2021) """	'D614G'	"""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Ferreira et al. (2021) """		"""Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""vaccine neutralization efficacy"""	"""Wang et al. (2021) """		"""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Baum et al. (2020) """		"""Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Weisblum et al. (2020) """		"""Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Barnes et al. (2020) """		"""The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Greaney et al. (2020) """		"""Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Starr et al. (2021) """		"""Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""monoclonal antibody serial passage escape"""	"""Wang et al. (2021) """		"""Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro."""	True	Eta	VOI
MN908947.3	snp	23012	23012	p.E484K	c.G1450A	S	MISSENSE	G	A	3269	3278	9	B.1.525	"""virion structure"""	"""Spratt et al. (2021) """		"""Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) """	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""syncytium formation"""	"""Kim et al. (2021) """		"""Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Kim et al. (2021) """		"""~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Kim et al. (2021) """		"""No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Kuzmina et al. (2021) """	'E484K'	"""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Barrett et al. (2021) """		"""Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Zhang et l. (2020) """		"""We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Ozono et al. (2020) """		"""Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. """	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""trafficking"""	"""Daniloski et al. (2021) """		"""The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""viral load"""	"""Plante et al. (2020) """		"""Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""convalescent plasma escape"""	"""Tada et al. (2021) """	'E484K'	"""Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""vaccine neutralization efficacy"""	"""Tada et al. (2021) """	'E484K'	"""Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""vaccine neutralization efficacy"""	"""Kuzmina et al. (2021) """	'E484K'	"""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""vaccine neutralization efficacy"""	"""Kuzmina et al. (2021) """		"""Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. """	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""vaccine neutralization efficacy"""	"""Garcia-Beltran et al. (2021) """		"""Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""virion structure"""	"""Zhang et al. (2020) """		"""Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""virion structure"""	"""Yurkovetskiy et al. (2020) """		"""CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""virion structure"""	"""Weissman et al. (2020) """		"""Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."""	True	Eta	VOI
MN908947.3	snp	23403	23403	p.D614G	c.A1841G	S	MISSENSE	A	G	3277	3279	2	B.1.525	"""virion structure"""	"""Spratt et al. (2021) """		"""Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) """	True	Eta	VOI
MN908947.3	snp	23593	23593	p.Q677H	c.G2031C	S	MISSENSE	G	C	3268	3277	8	B.1.525	"""transmissibility"""	"""Albertsen et al. (2021) """	'Q52R', 'E484K', 'F888L'	"""The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021)."""	True	Eta	VOI
MN908947.3	snp	24224	24224	p.F888L	c.T2662C	S	MISSENSE	T	C	3260	3272	12	B.1.525	"""transmissibility"""	"""Albertsen et al. (2021) """	'Q52R', 'E484K', 'Q677H'	"""The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021)."""	True	Eta	VOI
MN908947.3	snp	24748	24748	p.F1062F	c.C3186T	S	SILENT	C	T	3269	3277	8	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	26305	26305	p.L21F	c.C61T	E	MISSENSE	C	T	2584	2654	70	B.1.525	""""""	""""""		""""""	True	Eta	VOI
MN908947.3	snp	26767	26767	p.I82T	c.T245C	M	MISSENSE	T	C	3276	3278	2	B.1.525	"""homoplasy"""	"""Shen et al. (2021) """		"""This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds."""	True	Eta	VOI
MN908947.3	del	27204	27206	p.F2del	c.4_6delTTT	ORF6		GTTTCA	GCA	3189	3253	58	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	del	28277	28278	p.S2_D3delinsY	c.5_7delCTG	N		TCTGA	TA	3192	3257	34	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	28308	28308	p.A12G	c.C35G	N	MISSENSE	C	G	3227	3273	13	B.1.525	""""""	""""""		""""""	True	Eta	VOI
MN908947.3	snp	28699	28699	p.P142P	c.A426G	N	SILENT	A	G	3272	3276	3	B.1.525	""""""	""""""		""""""	False	Eta	VOI
MN908947.3	snp	28887	28887	p.T205I	c.C614T	N	MISSENSE	C	T	3263	3275	12	B.1.525	""""""	""""""		""""""	True	Eta	VOI
MN908947.3	snp	29543	29543	c.G-15T	c.G-15T	ORF10		G	T	3034	3139	105	B.1.525	""""""	""""""		""""""	False	Eta	VOI
